Objective-To derive a rational method of selecting the age range over which screening tests for cancer should be oVered (that is, over which they would be most effective in saving life). Main outcome measure-The number of person-years of life that are lost through deaths occurring at each year of age from each of six cancers. Results-For each cancer the number of years of life lost to age 80, plotted against age at death, showed a rise followed by a fall. The peak indicates the age at which deaths from the cancer result in most years of life lost. Special screening tests, such as mammography for breast cancer, will be most eVective in saving life shortly before that age. The peak (as a five year age span) occurs at age 55-59 for breast cancer (189 years of life lost per 10 000 women per year), 70-74 for prostate cancer (114), 65-69 for colorectal cancer (96), 55-59 for ovarian cancer (61), 50-54 for cervical cancer (47), and 45-50 for melanoma (8). The precise interval by which special screening tests should precede the peak age is not critical; five years would be appropriate. Given current evidence on the eYcacy of cancer screening, if it were stipulated that screening could only be performed when at least 50 years of life were to be gained per 10 000 persons screened, only mammography for breast cancer would be conducted, between the ages of 50 and 59. If the stipulation was 25 or more years of life gained mammography would be oVered to women aged 40-69 and cervical smears to women aged 35-59. With only 10 or more years of life gained (unlikely to be worthwhile) mammography would be extended to women aged 30-74, cervical smears to 25-69, and faecal occult blood testing for colorectal cancer oVered to those aged 45-74. Extending cervical cancer screening to age 69 would save more years of life than the present policy of screening women aged 20-29. Extending breast cancer screening to the age of 74 would be more eVective than cervical screening at any age. Conclusions-Determining the number of years of life lost through deaths from a particular cancer at each age is useful in public health screening policy, both in selecting the age range over which special screening tests of proven eYcacy should be oVered and in quantitatively comparing the value of screening for diVerent cancers. (J Med Screen 1999;6:16-20) 
In all cancer screening programmes it is necessary to specify the age at which people should first be invited for the test and the age at which they should no longer be invited. At present this choice of age range is somewhat arbitrary, and a rational method of determining it is needed. Such a method would in eVect treat age as an initial screening test. The selection of age has seldom been explicitly considered a screening test, but it is an important determinant of the success and cost eVectiveness of a programme.
The person-years of life lost from deaths at diVerent ages (the product of the death rate from a specific cancer and the average life expectancy at a given age) is a simple and equitable measure of quantifying the benefits of screening according to age. The age at which the deaths resulted in the largest number of years of life being lost is the age at which a screening procedure is most eVective, provided that there are no large age-specific diVerences in screening performance and treatment eYcacy. The same measure can be used in comparing the value of screening for diVerent cancers. Costs and other considerations being equal, a screening test for a cancer which, over a specified age range, prevented a larger number of life years lost should receive priority over a screening test for another disease which, over a diVerent age range, prevented a smaller number of life years lost.
In this paper we examine the "life years lost" concept as a simple means of determining the value of diVerent screening tests conducted over diVerent age ranges. We consider as examples six cancers-breast, cervix, colon and rectum (colorectal), ovary, prostate, and melanoma.
Methods
The number of years of life lost per 10 000 persons at each year of age was calculated as the product of the death rate and the average life expectancy (on 1990 death rates) at that age. For example the number of life years lost from breast cancer at age 50 (169 years per 10 000 women) was the product of the death rate from breast cancer in 50 year old women (5.5 deaths per 10 000 per year) and the life expectancy in a 50 year old women (30.7 years). The 10 000 persons were both sexes combined for colorectal cancer and melanoma but sex-specific for breast, cervical, ovarian, and prostate cancers. Our analyses were based on England and Wales mortality data from 1988 to 1992. For cervical cancer we used the earlier period 1940-64 to precede any eVect of screening on mortality; the wider interval was to minimise the higher risk in some birth cohorts than others (attributable to variation in sexual activity between cohorts). Mortality rates are published in five year age bands; rates at each single year of age were estimated by using cubic splines to fit a curve to the five yearly rates plotted against age.
We used published estimates of the relative reduction in mortality in persons who accept screening. For breast cancer, data from six trials indicate that mortality is 31% lower in screened women aged 50 and over. 1 In women under 50 screening may have a reduced eVect on mortality (the denser breast tissue in premenopausal women may render screening less sensitive); we judged that the estimate from the six trials that mortality was 19% lower in screened women was reasonable (although this was not statistically significantly diVerent from either zero or the 31% reduction in older women). 1 For colorectal cancer, data from two trials of two yearly faecal occult blood testing indicate that mortality is an estimated 25% lower in screened persons. 2 3 For cervical cancer, data from case-control studies indicate that three yearly cytological screening reduces mortality by an estimated 91%. 4 Screening for ovarian and prostate cancers and melanoma have not been shown to reduce mortality; the eVect of possible mortality reductions was assessed. Results Figure 1 shows the annual number of years of life lost through deaths from the six specified cancers occurring in 10 000 persons at each year of age in the absence of screening. All years lost (solid lines) and years lost up to age 80 (interrupted lines) are shown. There is typically an increase in the years of life lost from each cancer with increasing age at death, followed by a decline. The initial rise is because at younger ages the death rate increases with age more than life expectancy falls, the subsequent fall because at older ages life expectancy falls more than the death rate rises. Table 1 gives the numerical data used to construct fig 1. The estimated number of life years gained by screening for breast, cervical, and colorectal cancers are also shown. The special screening test for each cancer must anticipate the range of ages at death at which most life years are lost, preceding those ages by an interval that is neither too short (so that the diagnosis is too delayed to prevent death) nor too long (so that the cancer is too small to be detectable). For breast and colorectal cancer, randomised trials showed no reduction in mortality less than three years after the first screening test and the maximum reduction was attained after about five years. 2 5 We therefore took the age at which screening was most eVective to be five years earlier than the age at which deaths resulted in most years of life being lost. For breast cancer there was little reduction in mortality more than seven years after the last screening test, 5 but for cervical cancer a substantial protective eVect extended for 10 or more years after the last cervical smear. 4 The estimate of the total number of years of life gained will therefore be conservative. Figure 2 and table 2 translate years of life lost to years of life gained (or saved) based on the relative reduction in mortality from screening for breast, cervical, and colorectal cancers shown by randomised trials and other evidence. [1] [2] [3] [4] Figure 2 , based on the cervical cancer data used in table 1, shows the annual number of years of life lost up to age 80 owing to deaths from cervical cancer among 10 000 women at each year of age in the absence of screening, together with the number of years of life gained from screening. At the peak (age 50), 44 years of life can be gained per 10 000 women screened. By the age of 68, and at 39, this reduces to 25 years of life gained per 10 000 women screened and at ages 31 and 76 it is only 10 years of life gained. The figure shows how a small diVerence in the upper and lower limits of the age range across which special screening tests are oVered may have a large eVect on the marginal cost eVectiveness of screening. Table 2 shows the situation if a decision were made to oVer screening only if at least 50 years of life could be saved (up to age 80) per 10 000 women screened. Only breast cancer screening would be oVered, to women aged 50-59 years to target deaths in the age range 55-64. If the threshold were lowered to 25 years of life gained per 10 000 women, the range of age at death targeted would be 45-74 years for breast cancer (40-69 for age at mammography, or 50-69 if screening did not convey worthwhile benefit in women under 50 (see "Methods")). Also it would then, and only then, be rational and equitable to include cervical smears, targeted to reduce deaths in the age range 40-69 (rounding the estimates of 39 and 68 from fig 2) , and therefore oVered at age 35-64. At this marginal level of gain colorectal screening would still not be oVered. With a marginal 10 years of life gained per 10 000 persons (probably too small a gain to justify the cost), these age ranges would widen to 35-79 and 30-74 respectively, and screening for colorectal cancer would be acceptable, oVering occult blood testing to persons aged 45-74. The general approach could of course be modified according to diVerences in the costs of screening tests and investigation of screen positives. With improved accuracy of health service costings in general, the cost of various screening policies could be directly compared with other uses of health service resources that are accepted as being worthwhile. Evidence that screening reduces mortality is lacking for cancers of the ovary and prostate and for melanoma. The data in table 1 indicate that even if all deaths could be prevented, screening for melanoma at any age would probably not be worthwhile because of its rarity. If screening for prostate cancer halved mortality it would save about as many years of life at age 70 as mammography at age 55, and if ovarian cancer screening halved mortality it would gain slightly fewer years of life than screening for cervical cancer.
The numbers in table 2 are based on years of life lost to age 80. Increasing or decreasing this arbitrary age limit has relatively little impact on the choice of age range for breast and cervical cancers, because the peak for years of life lost occurs well below the age of 80 (fig 1) . The age limit chosen is important for colorectal (and prostate) cancers, where the upper part of the range will be principally determined by the limit; the special screening tests should be oVered so as to prevent deaths up to age 79 if the age limit is 80, or 74 if it is 75.
Discussion
Advantages of the method we propose are its simplicity and the ready availability of the necessary data from national mortality statistics. The method specifies the age range over which special screening examinations for a fatal disease should be routinely oVered to maximise the years of life saved for a given level of screening activity. If it had been adopted with cervical cancer screening it would have avoided the inappropriate policy of concentrating cervical smear examinations among younger women when deaths in older women caused most of the years of life lost from the disease. The method also permits a direct comparison of the potential gain in years of life saved when screening for diVerent disorders, to identify priorities. Screening for breast and cervical cancer (table 2) and (if screening reduced mortality) prostate cancer (table 1) oVers the greatest benefit from screening. Screening for melanoma has little potential: at best, if screening prevented nearly all deaths from melanoma (which is unlikely) it would save only about one tenth the number of years of life that breast cancer screening can save (see table 1 ). Death from testicular cancer is even rarer, yet screening programmes based on self examination have been advocated.
Although breast cancer screening reduces mortality by only about a third, among women aged 50-64 (or 55-69 at death in table 1) the number of years of life saved by screening exceeds that for cervical cancer and is close to the total number of years of life lost from ovarian cancer. The age range for the British mammography programme (50-64 years at screening) maximises the benefit over 15 years of periodic mammographic examinations. Invitations for mammography currently cease at age 64; extending them to age 69 would confer an absolute benefit similar to that conferred by cervical screening at any age. A similar benefit is possible in women aged 40-49, so the resolution of the uncertainty over the eVectiveness of screening in younger women is important.
In the British screening programme for cervical cancer, women are oVered a cervical smear examination between the ages of 20 and 64. More years of life are lost among women aged 70-74 (about 20 per 10 000 women) than among women under 30 (about four yearstable 1). Focusing on young women as was done a few years ago was illogical and ill-judged. Cervical smears in women aged 64 would prevent over half of the deaths occurring up to age 74 4 ; none the less, extending the offer of cervical smear examination to women aged 65-69 would be reasonable, preventing deaths up to the age of 80 and beyond.
The proposed method emphasises the importance of age as an initial screening test. Determining age is as much a screening test as a biochemical or x ray investigation if it is explicitly used as a mechanism for selecting those who will be oVered further tests. Its apparent simplicity conceals its importance. Such consideration of age should form the foundation of public health screening policy. Policy would be modified by further information on diVerences in costs of screening for different diseases, by future more specific data on whether screening and treatment have a similar quantitative benefit across the age range over which further tests will be oVered, by more precise estimates of lead time, and by quantitative data on morbidity and mortality. Such modifications could readily be incorporated, given the data.
A diYcult issue in determining the age range over which people should be invited for screening procedures is deciding whether the value ascribed to a year of life should be less in old age than in youth. An important advantage of the life years lost approach is that it allows for life expectancy being lower in old age. The only issue is whether the quality, or value, of a day of life declines as people age. Younger people may have dependants and generate income, but we believe that it is undesirable to ascribe diVerential judgments on the worth and quality of life at older ages. If the contrary arguments were generally accepted a lower weight might be placed on a year of life in an older than a younger person and the calculations modified. However, the voluntary nature of screening oVers a pragmatic solution to this problem. In choosing whether to accept an invitation for a screening test, people decide for themselves whether it is worthwhile; if they decide that it is that should be suYcient. The rate of response to an invitation for screening is generally not materially lower in older people, [6] [7] [8] but even if it were it would not be a good reason for limiting the age range: this would be unjust for those who wish to have access to a screening programme. Screening programmes consider the uptake rate when determining the number of invitations issued for each screening session and the only impact on cost eVectiveness would be the small additional cost of posting a higher proportion of unaccepted screening invitations.
